Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|September 19, 2017
Unither Pharmaceuticals
Unither Pharmaceuticals is a unique development and manufacturing partner for proprietary and generic dosage forms, and a global leader in single unit dose technologies such as sterile blow-fill-seal, and liquid and powder stick-packs
Advertisement
Unither Pharmaceuticals is a unique development and manufacturing partner for proprietary and generic dosage forms, and a global leader in single unit dose technologies such as sterile blow-fill-seal, and liquid and powder stick-packs. Unither’s focus is delivering medicines that are convenient, affordable, and easy-to-use. Unither technology benefits patients by offering improved dosing safety and compliance with pre-measured, correct dosing that reduces the risk of medication errors.
755 Jefferson Road
Rochester, NY 14623, USA
anthony.reda@unither-pharma.com
tel. +1.585.475.9000
fax. +1.585.272.3905
AAPS Booth #2515
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement